Author

Stefan Schreiber

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

Stefan Schreiber  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Stefan Schreiber  et al.

EUROPEAN AND UNITED STATES PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE TO SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
EUROPEAN AND UNITED STATES PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE TO SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Stefan Schreiber  et al.

BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Stefan Schreiber  et al.

CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL
CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL

Stefan Schreiber  et al.

EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Stefan Schreiber  et al.

PHOSPHOGLYCERATE DEHYDROGENASE PLAYS A VITAL ROLE IN ER-STRESS-RELATED INTESTINAL INFLAMMATION
PHOSPHOGLYCERATE DEHYDROGENASE PLAYS A VITAL ROLE IN ER-STRESS-RELATED INTESTINAL INFLAMMATION

Stefan Schreiber  et al.

TRYPTOPHAN DEGRADATION PRODUCTS AS UNIFYING BIOMARKERS OF SEVERITY AND LONG-TERM DISEASE CONTROL IN CHRONIC INFLAMMATORY DISEASES
TRYPTOPHAN DEGRADATION PRODUCTS AS UNIFYING BIOMARKERS OF SEVERITY AND LONG-TERM DISEASE CONTROL IN CHRONIC INFLAMMATORY DISEASES

Stefan Schreiber  et al.

PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY
PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY

Stefan Schreiber  et al.

PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY
PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY

Stefan Schreiber  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Stefan Schreiber  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Stefan Schreiber  et al.

Item 61 - 72 / 72
1 2 3
4